8-K: Indivior to Consolidate Primary Listing on Nasdaq, Cancels London Stock Exchange Secondary Listing

Indivior PLC announced its intention to cancel its secondary listing on the London Stock Exchange, effective July 25, 2025, to consolidate its primary listing on Nasdaq, citing U.S. revenue focus and higher Nasdaq liquidity.

Summary

• Indivior PLC intends to cancel its secondary listing on the London Stock Exchange (LSE), which includes its listing on the U.K. Financial Conduct Authority's (FCA) Official List and admission to trading on the LSE's main market for listed securities.
• The "London Delisting" is expected to become effective from 8:00 a.m. U.K. time on July 25, 2025, with the last date of trading of Ordinary Shares on the LSE being July 24, 2025.
• The company's primary listing on the Nasdaq Stock Market (symbol INDV) will be maintained and is unaffected by this delisting.
• Key reasons for the delisting include aligning with Indivior's most attractive opportunity set (U.S. SUBLOCADE), reflecting that over 80% of net revenue is generated from the U.S., eliminating the cost and complexity of maintaining a secondary listing, and acknowledging that Nasdaq now accounts for approximately 75% of total trading volume across both exchanges over the last 30 days as of May 27, 2025.
• Additionally, over 70% of Ordinary Shares by value are held by shareholders located in the U.S., and the delisting permits timing of material news announcements to align with the Company's U.S. peer set.
• No shareholder approval is required for the London Delisting as the Company is assigned to the Equity Shares (Transition) category of the Official List.
• The U.K. Takeover Code will continue to apply to Indivior for a period of two years after the London Delisting becomes effective.

Sentiment

Score: 7

Explanation: The announcement is a strategic, proactive move aimed at optimizing the company's listing structure and reducing complexity, which is generally positive. While it involves some administrative burden and potential costs for certain UK shareholders, the overall strategic rationale for aligning with the dominant U.S. market and investor base is sound.

Positives

• Fully aligns with Indivior's most attractive and valuable opportunity set, which is U.S. SUBLOCADE.
• Better reflects the Company's geographic net revenue profile, with over 80% of net revenue generated from the U.S.
• Eliminates the cost and complexity associated with maintaining a secondary listing.
• Recognizes that liquidity on Nasdaq now significantly outweighs liquidity on the LSE, with Nasdaq accounting for approximately 75% of total trading volume across both exchanges over the last 30 days as of May 27, 2025.
• Takes into account the location of most holders of Ordinary Shares by value, with over 70% now held by shareholders located in the U.S.
• Permits timing of material news announcements that aligns with the Company's U.S. peer set.
• Expected reductions in cost and complexity.

Negatives

• Holders of U.K. issued Indivior Depositary Interests (UK DIs) and participants in Indivior's Corporate Sponsored Nominee facility (CSN) will need to take specific actions to trade their shares on Nasdaq.
• Cancellation of UK DIs is subject to a charge, with a minimum cancellation charge currently at $125.
• CSN participants trading through the existing service might be exposed to fluctuations in exchange rates between U.S. dollars (Nasdaq settlement currency) and pounds sterling (default CSN sale proceeds currency).
• Withdrawing from the CSN facility and receiving Ordinary Shares directly in certificated form on a U.S. share register could expose shareholders to a future stamp duty liability of 1.5% of the value of their Ordinary Shares when subsequently trading on Nasdaq.

Risks

• Forward-looking statements inherently involve risks and uncertainties, and actual results may differ materially from those expressed or implied.
• The U.K. Takeover Code will continue to apply to the Company for two years after the London Delisting, meaning a mandatory cash offer could be required if any person acquires an interest in Ordinary Shares carrying 30% or more of the voting rights, or increases their interest above 30% but below 50%.

Future Outlook

Indivior expects the London Delisting to become effective and anticipates capitalizing on the expected benefits, including reductions in cost and complexity. The company also aims to align its material news announcements with its U.S. peer set, reinforcing its strategic focus on the U.S. market and its vision for global access to opioid use disorder treatment.

Management Comments

• "We are pleased to announce this key milestone for Indivior following our evaluation period. A single primary listing on Nasdaq best reflects the profile of Indivior's business." David Wheadon, Chair.
• "We appreciate the support received from shareholders for this initiative and look forward to capitalizing on the expected benefits of this move, including reductions in cost and complexity." David Wheadon, Chair.

Industry Context

This strategic move by Indivior to consolidate its listing on Nasdaq reflects a broader trend among global companies to optimize their market presence by focusing on the exchange that best aligns with their core business operations, primary revenue streams, and dominant investor base. For a pharmaceutical company like Indivior, with a significant focus on the U.S. market for opioid use disorder treatments, consolidating its listing in the U.S. can enhance visibility among relevant investors and streamline regulatory compliance, potentially improving market efficiency and reducing administrative overhead.

Comparison to Industry Standards

• The document does not provide specific comparisons to other companies' delisting processes or financial performance benchmarks.
• The rationale for delisting (U.S. revenue focus, U.S. shareholder base, Nasdaq liquidity) is a common strategic consideration for companies with dual listings where one market significantly dominates in terms of activity and investor interest, aligning with standard corporate finance practices for optimizing capital structure and market access.

Corporate Governance

Stakeholder Impact

• Shareholders (U.S. based): No direct impact, as the Nasdaq listing is maintained, potentially benefiting from increased liquidity concentration.
• Shareholders (U.K. based, especially UK DI and CSN holders): Will need to take administrative actions to trade shares on Nasdaq, potentially incurring costs (e.g., cancellation fees, stamp duty) and exposure to exchange rate fluctuations.
• Employees: The document mentions the board's views on the effects of an offer on employment and locations of business in the context of the Takeover Code, but no direct impact from the delisting itself is stated.
• Customers/Suppliers/Creditors: No direct impact mentioned in the document.

Next Steps

• The London Delisting is expected to become effective from 8:00 a.m. U.K. time on July 25, 2025.
• UK DI holders will need to reposition their interests in Ordinary Shares into a DTC broker or custodian account to trade on Nasdaq.
• CSN participants may sell their interests via Computershare's Internet Sales Service (by July 21, 2025, 4:30 p.m. U.K. time for UK residents) or Postal Dealing Service (by July 18, 2025, 5:30 p.m. U.K. time for non-UK residents).
• CSN participants may also withdraw from the CSN facility to reposition their UK DIs to a broker/custodian account in CREST or receive certificated shares on a U.S. share register.
• The U.K. Takeover Code will continue to apply to the Company for a period of two years after the London Delisting.

Key Dates

Recommendation

Keywords

Indivior PLC, INDV, London Stock Exchange, LSE, Nasdaq, Delisting, Secondary Listing, Primary Listing, Opioid Use Disorder, OUD, SUBLOCADE, Pharmaceutical, SEC Filing, 8-K, Corporate Governance, Shareholder Value, Trading Volume, U.S. Market, UK Takeover Code